BAFNA PHARMACEUTICALS LIMITED |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 86 INR | -0.98% |
|
-0.92% | -6.52% |
| Sales 2022 | 851M 10.21M | Sales 2023 | 1.15B 13.84M | Capitalization | 1.94B 23.27M |
|---|---|---|---|---|---|
| Net income 2022 | 51M 612K | Net income 2023 | 113M 1.36M | EV / Sales 2022 | 3.65 x |
| Net Debt 2022 | 109M 1.31M | Net Debt 2023 | 151M 1.81M | EV / Sales 2023 | 1.81 x |
| P/E ratio 2022 |
58.4
x | P/E ratio 2023 |
17.1
x | Employees | 588 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 10.23% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.98% | ||
| 1 week | -0.92% | ||
| Current month | +9.76% | ||
| 1 month | +10.04% | ||
| 3 months | -11.79% | ||
| 6 months | +3.06% | ||
| Current year | -6.52% |
1 week
83.25
89.95
1 month
75.9092.70
Current year
75.90107.80
1 year
75.90124.45
3 years
75.90185.50
5 years
4.40233.55
10 years
4.40233.55
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 62 | 80-12-31 | |
M. Sridhar
DFI | Director of Finance/CFO | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 62 | 80-12-31 | |
Krishna Yeachuri
BRD | Director/Board Member | 63 | 23-06-25 |
| Director/Board Member | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 86 | -0.98% | 1,496 |
| 24-04-25 | 86.85 | +0.40% | 12,235 |
| 24-04-24 | 86.5 | +0.58% | 21,254 |
| 24-04-23 | 86 | +0.82% | 1,695 |
| 24-04-22 | 85.3 | -1.73% | 526 |
End-of-day quote NSE India S.E., April 25, 2024
More quotes
Bafna Pharmaceuticals Limited is an India-based company, which is engaged in the manufacture of drugs and medicines and selling a reputed brand namely RARICAP. The Company caters to both domestic and international market. It operates in generic pharmaceutical segment. The Company manufactures 336 licensed pharmaceutical formulations and have globally registered 78 of its products. It supplies its products to the United Kingdom, Europe, and Australian markets. The Company's Grantlyon facility has the capability to supply both small-scale clinical trial quantities and commercial-scale requirements. The Companyâs subsidiary is Bafna Lifestyles Remedies Limited.
Sector
Pharmaceuticals
Calendar
2024-05-26
- Q4 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -6.52% | 24.39M | |
| +19.62% | 43.34B | |
| +20.44% | 21.96B | |
| +10.86% | 14.09B | |
| +13.07% | 13.64B | |
| +37.46% | 11.43B | |
| -8.59% | 6.86B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +8.46% | 5.22B |
- Stock Market
- Equities
- BAFNAPH Stock
